Comparing the anti-type 2 collagen antibody titer in rheumatoid factor negative vs. rheumatoid factor positive sera

AUTHORS

F Karimi 1 , * , N Firoozmanesh 1

AUTHORS INFORMATION

1 Iran

How to Cite: Karimi F, Firoozmanesh N. Comparing the anti-type 2 collagen antibody titer in rheumatoid factor negative vs. rheumatoid factor positive sera, J Kermanshah Univ Med Sci. 2002 ; 6(2):e81006.

ARTICLE INFORMATION

Journal of Kermanshah University of Medical Sciences: 6 (2); e81006
Published Online: September 19, 2002
Article Type: Research Article
Received: April 11, 2002
Accepted: September 11, 2002

Crossmark

CHEKING

READ FULL TEXT
Abstract

Introduction and Objectives: This study was done to determine   the anti-type 2 collagen (anti cII) antibody titer  in rheumatoid factor negative(RF-)  vs. rheumatoid factor positive(RF+)   sera.

 Materials and Methods: 77 RF+  and 221 RF- sera were examined for presence and titer of  anti-type 2 collagen antibody, using the tannic acid hemagglutination method. 

 Results: Anti cII antibody was found in 67.5% and 57.9% of RF+ and RF- cases, respectively.There was no significant difference  between RF- vs. RF+ sera regarding the presence of anti cII antibody . However, there was a significant difference (p<0.001)   between RF- vs. RF+ sera regarding the titer of anti cII antibody, with significantly higher antibody levels in RF+ sera.

Discussion and Conclusions: We suggest further   studying the correlation between  anti cII antibody, RF, and disease severity in rheumatoid arthritis is worthwhile.

Keywords

Collagen autoimmunity rheumatoid factor

© 2002, Journal of Kermanshah University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.

Fulltext

The full text of this article is available on PDF

COMMENTS

LEAVE A COMMENT HERE: